Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Maxygen has filed a clinical trial authorization and received the necessary approvals in the UK to initiate a first-in-human Phase I trial of Maxy-VII in hemophilia patients.
Subscribe to our email newsletter
Maxy-VII is the company’s next-generation Factor VIIa protein for the treatment of hemophilia. Patient dosing is on schedule to begin in the second half of 2008.
Russell Howard, CEO of Maxygen, said: “I’d like to congratulate our clinical team for meeting its goal of filing a clinical trial authorization in the first half of 2008, and for obtaining a rapid approval.
In addition to expedient management of Maxy-VII, the team has kept the Maxy-G34 G-CSF Phase IIa program moving forward on schedule. We expect to be able to share preliminary results from that program by the end of 2008.”